Analysts Offer Insights on Healthcare Companies: Spark Therapeutics (NASDAQ: ONCE) and Novadaq (NASDAQ: NVDQ)

By Jason Carr

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Spark Therapeutics (NASDAQ: ONCE) and Novadaq (NASDAQ: NVDQ).

Spark Therapeutics (NASDAQ: ONCE)

In a report issued on November 3, Cory Kasimov from J.P. Morgan reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE), with a price target of $82. The company’s shares closed last Friday at $44.10.

According to TipRanks.com, Kasimov is ranked 0 out of 5 stars with an average return of -15.8% and a 23.2% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Karyopharm Therapeutics, and ACADIA Pharmaceuticals.

Spark Therapeutics has an analyst consensus of Moderate Buy.

Novadaq (NASDAQ: NVDQ)

In a report issued on November 2, Sean Lavin from BTIG reiterated a Hold rating on Novadaq (NASDAQ: NVDQ). The company’s shares closed last Friday at $9.41.

According to TipRanks.com, Lavin is a 5-star analyst with an average return of 11.1% and a 60.9% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Trivascular Technologies, and Boston Scientific Corp.

Novadaq has an analyst consensus of Strong Buy, with a price target consensus of $17.